ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olokizumab

Also written as “CDP6038”, “Olokizumab” and “OKZ q4w”.

Its studies are mostly in Arthritis, Rheumatoid · COVID-19 · Polymyalgia Rheumatica · Arthritis, Juvenile · Lung Diseases, Interstitial, led by 2 companies.

Drug pageOlokizumab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 29, 201619 company-led studies, 3 open or runningNext primary completion: Apr 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
R-Pharmits history only113 open or runningphase 3since Apr 29, 2016Apr 29, 2016Apr 9, 2027phase 3 · NCT06440746
UCB80 open or runningphase 2since Nov 4, 2009Nov 4, 2009none ahead

Also a collaborator on its studies: Keystat, Exacte Labs, Data Management 365, IQVIA Pvt., Quintiles, K-Research, Cromos Pharma and Covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of UCB only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2009First study: phase 2 study in ArthritisFirst studyNCT01009242 · 40 enrolled · United States, Germany
  2. Nov 15, 2010Phase 2 study in Arthritis, RheumatoidNCT01242488 · 221 enrolled · United States, Belgium, United Kingdom
  3. Dec 16, 2010Phase 1 study in Healthy VolunteersNCT01262794 · 20 enrolled · United Kingdom
  4. Jan 11, 2011Phase 1 study in PharmacokineticsNCT01276119 · 67 enrolled · Germany
  5. Feb 14, 2011Phase 2 study in Arthritis, RheumatoidNCT01296711 · 190 enrolled · United States, Belgium, United Kingdom
  6. Oct 27, 2011Phase 2 study in Arthritis, RheumatoidNCT01463059 · 119 enrolled · Japan, Korea, Republic of, Taiwan
  7. Feb 10, 2012Phase 2 study in Arthritis, RheumatoidNCT01533714 · 103 enrolled · Japan, Korea, Republic of, Taiwan
  8. Jul 3, 2012Phase 2 study in Crohn DiseaseNCT01635621

TargetBeta

IL6 →read by rule
“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), ”NCIt, by rule
“Interleukin-6 inhibitor”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
ziltivekimabruleNovo Nordiskphase 312
clazakizumabCSLphase 310
pacibekitugruleNovartisphase 31
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

All 8 UCB leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01635621Crohn Disease2WithdrawnAug 20130
NCT01533714Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan2TerminatedNov 27, 2013103
NCT01463059Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan2CompletedFeb 2013119
NCT01296711Arthritis, Rheumatoid · United States, Belgium, United Kingdom2TerminatedMay 1, 2013190
NCT01276119Pharmacokinetics · Germany1CompletedOct 200967
NCT01262794Healthy Volunteers · United Kingdom1CompletedSep 201120
NCT01242488Arthritis, Rheumatoid · United States, Belgium, United Kingdom2CompletedJun 2012221
NCT01009242Arthritis · United States, Germany2CompletedSep 201040

How it is read

Names in the registry

  • “CDP6038”, 13 entries
  • “Olokizumab”, 5 entries
  • “OKZ q4w”, 2 entries
  • “CDP6038 (olokizumab)”, 2 entries
  • “Olokizumab 64 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.